151 related articles for article (PubMed ID: 35964311)
1. [HIV Restriction Factor APOBEC3G and Prospects for Its Use in Gene Therapy for HIV].
Tikhonov AS; Mintaev RR; Glazkova DV; Bogoslovskaya EV; Shipulin GA
Mol Biol (Mosk); 2022; 56(4):546-556. PubMed ID: 35964311
[TBL] [Abstract][Full Text] [Related]
2. Simian Immunodeficiency Virus Vif and Human APOBEC3B Interactions Resemble Those between HIV-1 Vif and Human APOBEC3G.
Wang J; Shaban NM; Land AM; Brown WL; Harris RS
J Virol; 2018 Jun; 92(12):. PubMed ID: 29618650
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 viral infectivity factor (Vif) alters processive single-stranded DNA scanning of the retroviral restriction factor APOBEC3G.
Feng Y; Love RP; Chelico L
J Biol Chem; 2013 Mar; 288(9):6083-94. PubMed ID: 23316055
[TBL] [Abstract][Full Text] [Related]
4. Differential anti-APOBEC3G activity of HIV-1 Vif proteins derived from different subtypes.
Iwabu Y; Kinomoto M; Tatsumi M; Fujita H; Shimura M; Tanaka Y; Ishizaka Y; Nolan D; Mallal S; Sata T; Tokunaga K
J Biol Chem; 2010 Nov; 285(46):35350-8. PubMed ID: 20833716
[TBL] [Abstract][Full Text] [Related]
5. [Advances in the study of molecular mechanism of APOBEC3G anti-HIV-1].
Fan B; Cen S; Jiang JD
Yao Xue Xue Bao; 2008 Jul; 43(7):678-82. PubMed ID: 18819469
[TBL] [Abstract][Full Text] [Related]
6. APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis.
Sadler HA; Stenglein MD; Harris RS; Mansky LM
J Virol; 2010 Jul; 84(14):7396-404. PubMed ID: 20463080
[TBL] [Abstract][Full Text] [Related]
7. The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H.
Binka M; Ooms M; Steward M; Simon V
J Virol; 2012 Jan; 86(1):49-59. PubMed ID: 22013041
[TBL] [Abstract][Full Text] [Related]
8. Polyubiquitination of APOBEC3G is essential for its degradation by HIV-1 Vif.
Shao Q; Wang Y; Hildreth JE; Liu B
J Virol; 2010 May; 84(9):4840-4. PubMed ID: 20147392
[TBL] [Abstract][Full Text] [Related]
9. Anti-APOBEC3G activity of HIV-1 Vif protein is attenuated in elite controllers.
Kikuchi T; Iwabu Y; Tada T; Kawana-Tachikawa A; Koga M; Hosoya N; Nomura S; Brumme ZL; Jessen H; Pereyra F; Trocha A; Walker BD; Iwamoto A; Tokunaga K; Miura T
J Virol; 2015 May; 89(9):4992-5001. PubMed ID: 25717111
[TBL] [Abstract][Full Text] [Related]
10. DNAJB8 facilitates autophagic-lysosomal degradation of viral Vif protein and restricts HIV-1 virion infectivity by rescuing APOBEC3G expression in host cells.
Chand K; Barman MK; Ghosh P; Mitra D
FASEB J; 2023 Mar; 37(3):e22793. PubMed ID: 36723955
[TBL] [Abstract][Full Text] [Related]
11. Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n.
Refsland EW; Hultquist JF; Harris RS
PLoS Pathog; 2012; 8(7):e1002800. PubMed ID: 22807680
[TBL] [Abstract][Full Text] [Related]
12. Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein.
Pery E; Sheehy A; Nebane NM; Brazier AJ; Misra V; Rajendran KS; Buhrlage SJ; Mankowski MK; Rasmussen L; White EL; Ptak RG; Gabuzda D
J Biol Chem; 2015 Apr; 290(16):10504-17. PubMed ID: 25724652
[TBL] [Abstract][Full Text] [Related]
13. Various strategies for developing APOBEC3G protectors to circumvent human immunodeficiency virus type 1.
Bao Q; Zhou J
Eur J Med Chem; 2023 Mar; 250():115188. PubMed ID: 36773550
[TBL] [Abstract][Full Text] [Related]
14. APOBEC3G-UBA2 fusion as a potential strategy for stable expression of APOBEC3G and inhibition of HIV-1 replication.
Li L; Liang D; Li JY; Zhao RY
Retrovirology; 2008 Aug; 5():72. PubMed ID: 18680593
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation.
Santa-Marta M; da Silva FA; Fonseca AM; Goncalves J
J Biol Chem; 2005 Mar; 280(10):8765-75. PubMed ID: 15611076
[TBL] [Abstract][Full Text] [Related]
16. Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding.
Mehle A; Wilson H; Zhang C; Brazier AJ; McPike M; Pery E; Gabuzda D
J Virol; 2007 Dec; 81(23):13235-41. PubMed ID: 17898068
[TBL] [Abstract][Full Text] [Related]
17. Differential sensitivity of "old" versus "new" APOBEC3G to human immunodeficiency virus type 1 vif.
Goila-Gaur R; Khan MA; Miyagi E; Strebel K
J Virol; 2009 Jan; 83(2):1156-60. PubMed ID: 19004939
[TBL] [Abstract][Full Text] [Related]
18. Identification of an HIV-1 replication inhibitor which rescues host restriction factor APOBEC3G in Vif-APOBEC3G complex.
Zhang S; Zhong L; Chen B; Pan T; Zhang X; Liang L; Li Q; Zhang Z; Chen H; Zhou J; Luo H; Zhang H; Bai C
Antiviral Res; 2015 Oct; 122():20-7. PubMed ID: 26241003
[TBL] [Abstract][Full Text] [Related]
19. Genetic and functional characterization of HIV-1 Vif on APOBEC3G degradation: First report of emergence of B/C recombinants from North India.
Ronsard L; Raja R; Panwar V; Saini S; Mohankumar K; Sridharan S; Padmapriya R; Chaudhuri S; Ramachandran VG; Banerjea AC
Sci Rep; 2015 Oct; 5():15438. PubMed ID: 26494109
[TBL] [Abstract][Full Text] [Related]
20. A naturally occurring Vif mutant (I107T) attenuates anti-APOBEC3G activity and HIV-1 replication.
Peng J; Ao Z; Matthews C; Wang X; Ramdahin S; Chen X; Li J; Chen L; He J; Ball B; Fowke K; Plummer F; Embree J; Yao X
J Mol Biol; 2013 Aug; 425(16):2840-52. PubMed ID: 23707381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
